SAB Biotherapeutics (NASDAQ:SABS) Earns “Buy” Rating from Chardan Capital

SAB Biotherapeutics (NASDAQ:SABS)‘s stock had its “buy” rating restated by stock analysts at Chardan Capital in a research report issued to clients and investors on Thursday,Benzinga reports. They presently have a $20.00 price objective on the stock.

Separately, HC Wainwright began coverage on SAB Biotherapeutics in a research report on Wednesday. They set a “buy” rating and a $10.00 price target for the company. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat, SAB Biotherapeutics has an average rating of “Buy” and a consensus target price of $12.20.

SAB Biotherapeutics Stock Performance

Shares of SABS opened at $1.85 on Thursday. The stock has a market capitalization of $17.19 million, a price-to-earnings ratio of -0.50 and a beta of 0.47. SAB Biotherapeutics has a 12 month low of $1.00 and a 12 month high of $5.01. The firm has a fifty day simple moving average of $1.52 and a 200 day simple moving average of $2.52. The company has a current ratio of 3.69, a quick ratio of 3.69 and a debt-to-equity ratio of 0.09.

SAB Biotherapeutics (NASDAQ:SABS) last issued its quarterly earnings results on Friday, May 9th. The company reported ($0.56) EPS for the quarter, topping the consensus estimate of ($1.00) by $0.44. SAB Biotherapeutics had a negative net margin of 1,450.14% and a negative return on equity of 94.37%. Research analysts forecast that SAB Biotherapeutics will post -3.69 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the company. HB Wealth Management LLC grew its holdings in SAB Biotherapeutics by 10.9% during the first quarter. HB Wealth Management LLC now owns 263,200 shares of the company’s stock worth $358,000 after purchasing an additional 25,800 shares during the period. Geode Capital Management LLC lifted its position in shares of SAB Biotherapeutics by 18.8% in the fourth quarter. Geode Capital Management LLC now owns 80,234 shares of the company’s stock valued at $307,000 after buying an additional 12,692 shares during the last quarter. Diadema Partners LP acquired a new stake in shares of SAB Biotherapeutics in the fourth quarter valued at approximately $114,000. Silver Oak Securities Incorporated bought a new position in shares of SAB Biotherapeutics during the 1st quarter worth approximately $30,000. Finally, Northern Trust Corp acquired a new position in shares of SAB Biotherapeutics during the 4th quarter worth approximately $43,000. 7.82% of the stock is currently owned by institutional investors and hedge funds.

About SAB Biotherapeutics

SAB Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases.